Loading...
Loading...
DMTK| Name | Value |
|---|---|
| Revenues | 3.8M |
| Cost of Revenue | 3.1M |
| Gross Profit | 0.7M |
| Operating Expense | 19.9M |
| Operating I/L | -19.2M |
| Other Income/Expense | -0.8M |
| Interest Income | 0.5M |
| Pretax | -20.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -20.0M |
DermTech, Inc. is a molecular diagnostic company in the United States that specializes in non-invasive genomics tests for skin cancer, inflammatory diseases, and aging-related conditions. Its flagship product, the DermTech Melanoma Test (DMT), is a gene expression test that aids in early detection of genomic atypia and helps rule out melanoma, reducing the need for surgical biopsies. The company also offers adhesive skin sample collection kits and gene expression assays for inflammatory pathways. It generates revenue by selling these products to pathology and oncology practitioners, and is also developing additional diagnostic and risk assessment products for skin cancer and related conditions.
